{
    "clinical_study": {
        "@rank": "124230", 
        "arm_group": {
            "arm_group_label": "ACCS", 
            "arm_group_type": "Experimental", 
            "description": "There will be 3 treatment cohorts of 10 patients each.  The area of the breast will be divided into two, roughly equal parts, medial and lateral.  The patient will be randomized before the first treatment to receive ACCS and saline, one to the medial segment and the other to the lateral segment.  The randomization scheme will be equal in each of three cohorts.  The first cohort will receive ACCS and saline beginning with the first radiation treatment, the second cohort will receive ACCS and saline beginning with the onset of erythema from the breast irradiation, the third cohort will receive ACCS and saline beginning with the onset of skin ulceration from the breast irradiation."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and efficacy of ACCS in treating\n      radiation burns of the skin in patients undergoing treatments for breast cancer and to\n      compare ACCS treated burns with those treated with saline placebo controls."
        }, 
        "brief_title": "Study of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline in Treating Skin Irritation From Radiation", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Radiation-induced Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Radiodermatitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A signed IRB - approved Informed Consent;\n\n          -  Women 18 - 80 years of age;\n\n          -  Biopsy-proven diagnosis of breast cancer with the tumor surgically removed.\n\n          -  Whole breast radiation with or without ipsilateral axilla radiation therapy\n             recommended by her radiation oncologist.\n\n          -  If a woman is of child-bearing potential, she and her partner must use an effective\n             form of birth control.\n\n          -  Willing to participate in the clinical study and comply with the requirements of the\n             trial.\n\n        Exclusion Criteria:\n\n          -  Abnormal liver or kidney function studies being greater than 2x the upper limit of\n             normal.\n\n          -  Patients on hemodialysis\n\n          -  Psychiatric condition or substance abuse which in the Investigator's opinion may pose\n             a threat to patient compliance;\n\n          -  History of non-compliance with treatment or clinical visit attendance.\n\n          -  Participation in an investigational trial within 30 days of study entry.\n\n          -  Women who are pregnant or lactating"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714973", 
            "org_study_id": "ST-02-12"
        }, 
        "intervention": {
            "arm_group_label": "ACCS", 
            "description": "Patients will receive ACCS spray,  to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments.  ACCS and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.", 
            "intervention_name": "ACCS", 
            "intervention_type": "Biological", 
            "other_name": "Amnion-derived Cellular Cytokine Solution (ACCS)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "shebda@wpahs.org", 
                "last_name": "Susan Hebda, BS, CCRC", 
                "phone": "412-359-4046"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15212"
                }, 
                "name": "Allegheny General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Randomized, Blinded Safety and Efficacy Trial of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline Sprayed on the Breast of Women Undergoing Radiation Therapy for Breast Cancer After Surgical Removal of the Tumor", 
        "other_outcome": {
            "description": "Cosmesis will be evaluated by photography and investigator assessment using the cosmesis form in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-39, A Randomized Phase III Study of Conventional Whole Breast Irradiation Versus Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer.  The following factors will be evaluated in the skin: telangiectasia, atrophy, scarring, pigmentation, erythema, fat necrosis, and fibrosis.", 
            "measure": "Cosmesis", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months post-treatment"
        }, 
        "overall_contact": {
            "email": "dsteed@stemnion.com", 
            "last_name": "David L Steed, MD", 
            "phone": "412-402-9926"
        }, 
        "overall_contact_backup": {
            "email": "ntatsis@stemnion.com", 
            "last_name": "Nia Tatsis, PhD", 
            "phone": "412-402-9972"
        }, 
        "overall_official": [
            {
                "affiliation": "West Penn Allegheny Health System", 
                "last_name": "Mark Trombetta, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Stemnion, Inc.", 
                "last_name": "David L Steed, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse Events (AEs) and Significant Adverse Events (SAEs)", 
            "safety_issue": "No", 
            "time_frame": "Start of therapy through six week follow-up visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714973"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Skin inflammation", 
                "safety_issue": "No", 
                "time_frame": "start of therapy through six week follow-up visit"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "start of therapy through one year follow-up"
            }
        ], 
        "source": "Stemnion, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stemnion, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}